A second endogenous molecular form of mammalian hypothalamic luteinizing hormone-releasing hormone LHRH hydroxyproline9 LHRH releases luteinizing hormone and follicle-stimulating hormone in vitro and ...

Abstract:  A second endogenous molecular form of mammalian hypothalamic luteinizing hormone-releasing hormone (LHRH), (hydroxyproline9)LHR H, releases luteinizing hormone and follicle-stimulating hormone in vitro and in vivo. Gautron JP, Leblanc P, Bluet-Pajot MT, Pattou E, L'H?ritier A, Mounier F, Ponce G, Audinot V, Rasolonjanahary R, Kordon C. Unit? de Dynamique des Syst?mes Neuroendocriniens (U159) de l'INSERM, Centre Paul Broca, Paris, France. In vitro and in vivo release of pituitary hormones were studied in the presence of (hydroxyproline9)LHR H ((Hyp)LHRH), a newly characterized endogenous molecular form of LHRH. Results were compared to those obtained with LHRH itself. (Hyp)LHRH, as LHRH, stimulated both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release in a homothetic manner. The hydroxylated compound was, however, 24 times (in vitro) and 5 times (in vivo) less potent than LHRH. The lower activity of (Hyp)LHRH than of LHRH in the in vitro assay correlated well with a 28-fold lesser potency in a binding test using pituitary membrane preparations. The higher relative potency and the prolonged effect of (Hyp)LHRH in the in vivo test were related to a lesser susceptibility of the hydroxylated form to proteolytic degradation. Effects of LHRH and of (Hyp)LHRH were not additive, both peptides were equally able to desensitize gonadotrophs to a subsequent challenge by the other. Taken together, these observations suggest that both forms of LHRH act at the same receptor site. The lesser affinity of the hydroxylated compound is compensated to a certain extent by its higher resistance to enzymatic degradation. It is concluded that in spite of its lesser potency, (Hyp)LHRH may participate in the regulation of gonadotropins. PMID : 1526318 [PubMed - indexed for MEDLINE]